肥大细胞激活剂化合物48/80用作炭疽芽孢杆菌保护性抗原皮内免疫佐剂时安全有效。
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
作者信息
McGowen Afton L, Hale Laura P, Shelburne Christopher P, Abraham Soman N, Staats Herman F
机构信息
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
出版信息
Vaccine. 2009 Jun 2;27(27):3544-52. doi: 10.1016/j.vaccine.2009.03.069. Epub 2009 Apr 14.
Abstract
We evaluated the safety and efficacy of the mast cell activator compound 48/80 (C48/80) when used as an adjuvant delivered intradermally (ID) with recombinant anthrax protective antigen (rPA) in comparison with two well-known adjuvants. Mice were vaccinated in the ear pinnae with rPA or rPA+C48/80, CpG oligodeoxynucleotides (CpG), or cholera toxin (CT). All adjuvants induced similar increases in serum anti-rPA IgG and lethal toxin neutralizing antibodies. C48/80 induced a balanced cytokine production (Th1/Th2/Th17) by antigen-restimulated splenocytes, minimal injection site inflammation, and no antigen-specific IgE. Histological analysis demonstrated that vaccination with C48/80 reduced the number of resident mast cells and induced an injection site neutrophil influx within 24h. Our data demonstrate that C48/80 is a safe and effective adjuvant, when used by the intradermal route, to induce protective antibody and balanced Th1/Th2/Th17 responses.
摘要
我们评估了肥大细胞激活剂化合物48/80（C48/80）与两种知名佐剂相比，皮内注射（ID）重组炭疽保护性抗原（rPA）时作为佐剂的安全性和有效性。用rPA或rPA + C48/80、CpG寡脱氧核苷酸（CpG）或霍乱毒素（CT）对小鼠耳廓进行疫苗接种。所有佐剂均诱导血清抗rPA IgG和致死毒素中和抗体出现相似程度的增加。C48/80通过抗原再刺激的脾细胞诱导了平衡的细胞因子产生（Th1/Th2/Th17），注射部位炎症轻微，且未产生抗原特异性IgE。组织学分析表明，接种C48/80可减少驻留肥大细胞数量，并在24小时内诱导注射部位中性粒细胞流入。我们的数据表明，皮内使用C48/80作为佐剂可诱导保护性抗体和平衡的Th1/Th2/Th17反应，是一种安全有效的佐剂。
相似文献
1
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.肥大细胞激活剂化合物48/80用作炭疽芽孢杆菌保护性抗原皮内免疫佐剂时安全有效。
Vaccine. 2009 Jun 2;27(27):3544-52. doi: 10.1016/j.vaccine.2009.03.069. Epub 2009 Apr 14.
2
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.新型佐剂鼻用疫苗的研发：与壳聚糖纳米颗粒结合的C48/80作为增强黏膜免疫的途径
Eur J Pharm Biopharm. 2015 Jun;93:149-64. doi: 10.1016/j.ejpb.2015.03.024. Epub 2015 Mar 26.
3
A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.比较非毒素疫苗佐剂增强经鼻给予炭疽重组保护性抗原免疫原性的能力。
Vaccine. 2013 Mar 1;31(11):1480-9. doi: 10.1016/j.vaccine.2013.01.012. Epub 2013 Jan 23.
4
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.对炭疽的有效黏膜免疫：用保护性抗原经鼻免疫后的中和抗体及Th细胞反应
J Immunol. 2003 Jun 1;170(11):5636-43. doi: 10.4049/jimmunol.170.11.5636.
5
Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.用新型纳米乳剂重组炭疽保护性抗原疫苗进行黏膜免疫可抵御炭疽芽孢杆菌孢子攻击。
Infect Immun. 2007 Aug;75(8):4020-9. doi: 10.1128/IAI.00070-07. Epub 2007 May 14.
6
Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.化合物48/80作为一种有效的黏膜佐剂，用于幼鼠抗肺炎链球菌感染的疫苗接种。
Vaccine. 2015 Feb 18;33(8):1008-16. doi: 10.1016/j.vaccine.2015.01.013. Epub 2015 Jan 14.
7
Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.用聚肌苷酸-聚胞苷酸佐剂辅助的炭疽保护性抗原蛋白进行鼻腔免疫可诱导强烈的黏膜和全身免疫。
Pharm Res. 2006 Jun;23(6):1217-26. doi: 10.1007/s11095-006-0206-9. Epub 2006 May 25.
8
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.一种用于炭疽保护性抗原的CpG-聚蔗糖纳米颗粒佐剂可增强免疫原性，并为猴子提供针对吸入性炭疽的单次免疫保护。
J Immunol. 2016 Jan 1;196(1):284-97. doi: 10.4049/jimmunol.1501903. Epub 2015 Nov 25.
9
Needle-free skin patch vaccination method for anthrax.用于炭疽的无针皮肤贴片疫苗接种方法。
Infect Immun. 2004 Feb;72(2):1181-3. doi: 10.1128/IAI.72.2.1181-1183.2004.
10
Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.颗粒佐剂对有效鼻腔接种所需炭疽保护性抗原剂量的影响。
Vaccine. 2015 Jul 17;33(31):3609-13. doi: 10.1016/j.vaccine.2015.06.037. Epub 2015 Jun 15.
引用本文的文献
1
Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.用48/80佐剂无细胞百日咳疫苗进行鼻腔免疫是诱导百日咳特异性全身和黏膜免疫的有效策略。
Clin Exp Vaccine Res. 2025 Jul;14(3):246-260. doi: 10.7774/cevr.2025.14.e23. Epub 2025 Apr 15.
2
DNA Methylation Negatively Regulates Gene Expression of Key Cytokines Secreted by BMMCs Recognizing FMDV-VLPs.DNA 甲基化负调控 BMMCs 识别 FMDV-VLPs 时分泌的关键细胞因子的基因表达。
Int J Mol Sci. 2024 Oct 9;25(19):10849. doi: 10.3390/ijms251910849.
3
Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG.基于蜂毒素 7 肽和 CpG 自组装颗粒佐剂研发的广谱流感鼻腔疫苗
Front Immunol. 2023 Mar 24;14:1103765. doi: 10.3389/fimmu.2023.1103765. eCollection 2023.
4
Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.使用缩醛化葡聚糖微球递呈小分子肥大细胞激活剂用于西尼罗河病毒疫苗接种。
Int J Pharm. 2023 Mar 5;634:122658. doi: 10.1016/j.ijpharm.2023.122658. Epub 2023 Jan 30.
5
Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.利用肥大细胞在非传统免疫治疗策略和疫苗佐剂中的作用。
Cells. 2020 Dec 18;9(12):2713. doi: 10.3390/cells9122713.
6
Mast Cell Functions Linking Innate Sensing to Adaptive Immunity.肥大细胞功能将先天感应与适应性免疫联系起来。
Cells. 2020 Nov 25;9(12):2538. doi: 10.3390/cells9122538.
7
Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.新型黏膜佐剂马斯托帕兰-7可提高可卡因疫苗的疗效。
NPJ Vaccines. 2020 Feb 5;5(1):12. doi: 10.1038/s41541-020-0161-1. eCollection 2020.
8
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.优化黏膜组织修饰安卡拉痘苗病毒初免/可溶性 gp120 加强型 HIV 疫苗接种方案诱导的抗体应答类似于肌肉内接种方案。
J Virol. 2019 Jun 28;93(14). doi: 10.1128/JVI.00475-19. Print 2019 Jul 15.
9
Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant.壳聚糖加复合48/80：作为乙肝疫苗佐剂的配方及初步评价。
Pharmaceutics. 2019 Feb 9;11(2):72. doi: 10.3390/pharmaceutics11020072.
10
Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.血管生成宿主防御肽 AG-30/5C 和缓激肽 B 受体拮抗剂 Icatibant 是肥大细胞中 MRGPRX2 的 G 蛋白偏向激动剂。
J Immunol. 2019 Feb 15;202(4):1229-1238. doi: 10.4049/jimmunol.1801227. Epub 2019 Jan 16.
本文引用的文献
1
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.10表位细胞毒性T淋巴细胞疫苗IDM-2101用于转移性非小细胞肺癌的II期试验中的免疫反应诱导及临床疗效
J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.
2
Anaphylaxis following quadrivalent human papillomavirus vaccination.四价人乳头瘤病毒疫苗接种后的过敏反应。
CMAJ. 2008 Sep 9;179(6):525-33. doi: 10.1503/cmaj.080916. Epub 2008 Sep 1.
3
B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones.B细胞趋化因子CXCL13优先由人Th17细胞克隆表达。
J Immunol. 2008 Jul 1;181(1):186-9. doi: 10.4049/jimmunol.181.1.186.
4
Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.使用皮内注射流感疫苗提高1岁以下婴儿的抗体反应。
Vaccine. 2008 May 23;26(22):2700-5. doi: 10.1016/j.vaccine.2008.03.016. Epub 2008 Mar 31.
5
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.低剂量皮内注射黄热病疫苗可诱导产生保护性免疫反应：一项随机对照非劣效性试验
PLoS One. 2008 Apr 23;3(4):e1993. doi: 10.1371/journal.pone.0001993.
6
Mast cell activators: a new class of highly effective vaccine adjuvants.肥大细胞激活剂：一类新型高效疫苗佐剂。
Nat Med. 2008 May;14(5):536-41. doi: 10.1038/nm1757. Epub 2008 Apr 20.
7
A sheep in wolf's clothes: can neutrophils direct the immune response?披着狼皮的羊：中性粒细胞能引导免疫反应吗？
Vet J. 2009 May;180(2):169-77. doi: 10.1016/j.tvjl.2007.12.030. Epub 2008 Mar 4.
8
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.用于在小鼠中诱导对流感疫苗产生强效、持久抗体和T细胞反应的联合佐剂。
Vaccine. 2008 Jan 24;26(4):552-61. doi: 10.1016/j.vaccine.2007.11.054. Epub 2007 Dec 7.
9
Th17 cells: effector T cells with inflammatory properties.辅助性T细胞17：具有炎症特性的效应T细胞。
Semin Immunol. 2007 Dec;19(6):362-71. doi: 10.1016/j.smim.2007.10.007. Epub 2007 Nov 26.
10
How do adjuvants work? Important considerations for new generation adjuvants.佐剂如何发挥作用？新一代佐剂的重要考量因素。
Immunity. 2007 Nov;27(5):687-90. doi: 10.1016/j.immuni.2007.11.003.
Zotero 插件